Autus Asset Management LLC Trims Holdings in Eli Lilly and Company (NYSE:LLY)

Autus Asset Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY – Get Rating) by 2.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,453 shares of the company’s stock after selling 38 shares during the period. Autus Asset Management LLC’s holdings in Eli Lilly and were worth $416,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. State Street Corp increased its stake in shares of Eli Lilly and by 2.5% during the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after purchasing an additional 813,983 shares in the last quarter. Capital World Investors increased its position in Eli Lilly and by 13.9% during the fourth quarter. Capital World Investors now owns 19,115,896 shares of the company’s stock worth $5,280,206,000 after purchasing an additional 2,325,514 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Eli Lilly and by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock worth $4,059,130,000 after buying an additional 409,009 shares during the period. Norges Bank purchased a new position in shares of Eli Lilly and in the 4th quarter worth about $2,213,765,000. Finally, Fisher Asset Management LLC lifted its position in Eli Lilly and by 7.2% during the fourth quarter. Fisher Asset Management LLC now owns 6,982,910 shares of the company’s stock valued at $1,928,820,000 after buying an additional 470,522 shares in the last quarter. 82.75% of the stock is owned by institutional investors and hedge funds.

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total transaction of $313,440.00. Following the completion of the sale, the chief accounting officer now owns 6,274 shares in the company, valued at approximately $1,966,522.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 7,538 shares of the firm’s stock in a transaction that occurred on Monday, March 28th. The shares were sold at an average price of $292.15, for a total value of $2,202,226.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 848,630 shares of company stock worth $259,239,945. Corporate insiders own 0.12% of the company’s stock.

A number of analysts have recently issued reports on the stock. StockNews.com lowered shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. upped their price objective on Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Morgan Stanley raised their price target on shares of Eli Lilly and from $364.00 to $369.00 in a research report on Friday, April 29th. SVB Leerink assumed coverage on Eli Lilly and in a research note on Monday, May 23rd. They set an “outperform” rating and a $341.00 price objective for the company. Finally, Wells Fargo & Company lifted their price target on Eli Lilly and from $280.00 to $305.00 in a report on Friday, April 29th. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $311.00.

NYSE:LLY opened at $306.69 on Thursday. The company has a market capitalization of $291.40 billion, a P/E ratio of 45.44, a P/E/G ratio of 2.06 and a beta of 0.40. The stock’s 50 day moving average price is $297.48 and its 200 day moving average price is $274.96. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. Eli Lilly and Company has a 52 week low of $217.00 and a 52 week high of $324.08.

Eli Lilly and (NYSE:LLY – Get Rating) last posted its earnings results on Thursday, April 28th. The company reported $2.62 EPS for the quarter, topping the consensus estimate of $2.32 by $0.30. The firm had revenue of $7.81 billion for the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The business’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.87 earnings per share. As a group, sell-side analysts forecast that Eli Lilly and Company will post 8.27 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Monday, May 16th were given a dividend of $0.98 per share. The ex-dividend date of this dividend was Friday, May 13th. This represents a $3.92 dividend on an annualized basis and a yield of 1.28%. Eli Lilly and’s payout ratio is currently 58.07%.

Eli Lilly and Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading